Skin Application of Inflammasome Inhibitor MCC950 Prevents Psoriasis-like Cutaneous Manifestations and Associated Systemic Inflammation - PubMed
3 hours ago
- #Topical treatment
- #Psoriasis
- #NLRP3 inflammasome
- Topical application of the NLRP3 inhibitor MCC950 suppresses NLRP3 inflammasome activation in the skin by preventing pro-caspase-1 cleavage.
- MCC950 inhibits expression of psoriasis hallmark genes (e.g., Il17, Tnf, S100a8/a9, Il1b) and reduces infiltration of immune cells like T cells and dendritic cells in the skin.
- MCC950 prevents systemic inflammation associated with psoriasis, including changes in spleen T cell phenotype and increased serum IL-6 levels.
- Network analysis identifies NLRP3 as a central hub in psoriasis-associated inflammation, supporting upstream targeting as a strategy to dampen multiple pathways.
- The study uses an imiquimod-induced psoriasis-like mouse model, highlighting MCC950's potential in inhibiting both cutaneous and systemic manifestations of psoriasis.